Recent Updates
Recently added Catalysts
KPRX Positive Sentiment

How KIO-401 Positions Kiora as a Late-Stage Retinal Therapeutics Company

Key Takeaway: Kiora Pharmaceuticals announced plans to initiate a multinational Phase 3 trial for KIO-401, an oral calpain inhibitor for central retinal artery occlusion (CRAO). The company also aims to conduct a Phase 2b trial for non-arteritic anterior ischemic optic neuropathy (NAION). KIO-401 addresses significant unmet needs in these conditions.
Price reaction · baseline $0.8248 (2026-11-18 close) · hit pre-market · clean, no other KPRX news in the window
day 0 close
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Kiora plans a multinational Phase 3 trial for KIO-401.
  • KIO-401 targets a significant unmet need in CRAO.
  • The company is expanding its research into NAION.

CONCERNS & RISKS

  • Actual results may differ from management's expectations.
  • Risks include feasibility of trial enrollment and funding.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
10.4%
average across 4 past catalysts
Cash runway
~87 mo
Low dilution risk
Lead asset
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75%
Phase 2 · Persistent Corneal Epithelial Defect

Full Press Release Details

San Diego, California--(Newsfile Corp. - November 19, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has posted an on-demand video featuring President and CEO Brian M. Strem, Ph.D., discussing the in-licensing of KIO-401 (mitucapistat), an investigational oral calpain inhibitor for sudden vision loss caused by central retinal artery occlusion (CRAO). Click here or on the following image to view the video.
Cannot view this video? Visit:
KIO-401 has been evaluated in Phase 2 and Phase 3 CRAO studies in Japan. Building on those studies, Kiora plans to initiate a multinational Phase 3 registration trial in CRAO in 2027. The company also plans to evaluate KIO-401 in a Phase 2b trial in non-arteritic anterior ischemic optic neuropathy (NAION).
The video interview will be available for 90 days in the Events section of Kiora’s investor relations website.
About Kiora
Kiora Pharmaceuticals is a late-stage retinal therapeutics company developing small-molecule therapies targeting differentiated biological pathways implicated in vision-threatening diseases.
KIO-401 is an oral, neuroprotective calpain inhibitor in development for central retinal artery occlusion (CRAO) and non-arteritic anterior ischemic optic neuropathy (NAION), two rare, acute ischemic ophthalmic diseases with no approved pharmacologic treatments. Kiora is planning a multinational Phase 3 registration trial in CRAO and a Phase 2b clinical trial in NAION. The KIO-401 platform also has potential applications in additional ophthalmic indications, including glaucoma, where calpain-mediated injury may contribute to disease progression.
KIO-301 is a partnered Phase 2 photoswitch therapy for advanced retinitis pigmentosa. KIO-104, a DHODH inhibitor previously evaluated in the KLARITY clinical trial for retinal inflammation and fibrosis, is available for partnering or out-licensing.
For more information, visit www.kiorapharma.com.
Forward-Looking Statements
This update contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Kiora's plans for KIO-401, the targeted 2027 start of a multinational Phase 3 registration trial in CRAO and the planned Phase 2b trial in NAION.
These statements reflect management's current expectations. Actual results could differ materially due to risks and uncertainties, including whether findings from prior studies in Japan can be replicated, whether regulatory feedback changes trial design or timing, the cost and feasibility of enrolling and conducting the trials, and Kiora's ability to raise sufficient capital to fund development. Additional risks are described under "Risk Factors" in Kiora's Annual Report on Form 10-K, filed March 25, 2026, and in subsequent SEC filings.
These statements speak as of the date of this update. Kiora disclaims any obligation to update them in light of later events or new information, except as required by law.
Contacts
Media
Susan Sharpe Linnden Communications susan@linndencom.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324751
Released November 19, 2026

Frequently Asked Questions

What is KIO-401?

KIO-401 is an investigational oral calpain inhibitor for vision loss.

What trials is Kiora planning for KIO-401?

Kiora plans a Phase 3 trial for CRAO and a Phase 2b trial for NAION.

What conditions does KIO-401 target?

KIO-401 targets central retinal artery occlusion and non-arteritic anterior ischemic optic neuropathy.

What are the risks associated with Kiora's plans?

Risks include trial enrollment feasibility and funding challenges.

Last updated: Nov 19, 2026